• United Therapeutics Corp., of Silver Spring, Md., said it received a second complete response letter (CRL) from the FDA, declining to approve its new drug application (NDA) for treprostinil diolamine extended-release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension (PAH).